Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBT Margin (2016 - 2025)

Historic EBT Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 92.91%.

  • Lineage Cell Therapeutics' EBT Margin fell 135000.0% to 92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 296.07%, marking a year-over-year decrease of 661600.0%. This contributed to the annual value of 195.62% for FY2024, which is 646600.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its EBT Margin stood at 92.91% for Q3 2025, which was down 135000.0% from 698.95% recorded in Q2 2025.
  • Lineage Cell Therapeutics' EBT Margin's 5-year high stood at 56.02% during Q4 2021, with a 5-year trough of 969.73% in Q2 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' median EBT Margin value was 260.14% (recorded in 2023), while the average stood at 318.95%.
  • In the last 5 years, Lineage Cell Therapeutics' EBT Margin skyrocketed by 12693600bps in 2021 and then plummeted by -3885200bps in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' EBT Margin stood at 56.02% in 2021, then plummeted by -493bps to 332.22% in 2022, then surged by 32bps to 225.77% in 2023, then surged by 50bps to 113.32% in 2024, then grew by 18bps to 92.91% in 2025.
  • Its EBT Margin stands at 92.91% for Q3 2025, versus 698.95% for Q2 2025 and 401.26% for Q1 2025.